Evidence map›Paper›PMID 39848295›Full record

ReviewInternational journal of radiation oncology, biology, physics2025

Embracing the Future of Clinical Trials in Radiation Therapy: An NRG Oncology CIRO Technology Retreat Whitepaper on Pioneering Technologies and AI-Driven Solutions.

Ying Xiao, Stanley Benedict, Yunfeng Cui, Carri Glide-Hurst, Stephen Graves, Xun Jia, Stephen F Kry, Heng Li, Liyong Lin, Martha Matuszak and 16 more

Erratum issuedAbstract readReview
In one paragraph

Review in International journal of radiation oncology, biology, physics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Fully GMP-complient radiosynthesis of [EJNMMI radiopharmacy and chemistry · 2026
    Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

26 authors.

Ying XiaoDepartment of Radiation Oncology, University of Pennsylvania, Philadelphia, Pennsylvania.
Stanley BenedictDepartment of Radiation Oncology, University of California at Davis, Comprehensive Cancer Center, Davis, California.
Yunfeng CuiDepartment of Radiation Oncology, Duke University, Durham, North Carolina.
Carri Glide-HurstDepartment of Human Oncology, University of Wisconsin, Madison, Wisconsin.
Stephen GravesDepartment of Radiology, Division of Nuclear Medicine, University of Iowa, Iowa City, Iowa.
Xun JiaDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University, Baltimore, Maryland.
Stephen F KryDepartment of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Heng LiDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University, Baltimore, Maryland.
Liyong LinDepartment of Radiation Oncology, Emory University, Atlanta, Georgia.
Martha MatuszakDepartment of Radiation Oncology, University of Michigan, Ann Arbor, Michigan.
Mark NewpowerDepartment of Radiation Oncology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma.
Harald PaganettiDepartment of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
X Sharon QiDepartment of Radiation Oncology, University of California Los Angeles, Los Angeles, California.
Emilie RoncaliDepartment of Radiology, University of California at Davis, Davis, California.
Yi RongDepartment of Radiation Oncology, Mayo Clinic, Rochester, Minnesota.
George SgourosDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University, Baltimore, Maryland.
Charles B SimoneNew York Proton Center, New York, New York.
John J SunderlandDepartment of Radiology, Division of Nuclear Medicine, University of Iowa, Iowa City, Iowa.
Paige A TaylorDepartment of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Leila TchelebiDepartment of Radiation Oncology, Northwell Health, Mt. Kisco, New York.
Michael WeldonDepartment of Radiation Oncology, The Ohio State University Medical Center, Columbus, Ohio.
Jennifer W ZouDepartment of Radiation Oncology, University of Pennsylvania, Philadelphia, Pennsylvania.
Evan J WuthrickDepartment of Radiation Oncology, Moffitt Cancer Center, Tampa, Florida.
Mitchell MachtayDepartment of Radiation Oncology, Penn State Health Milton S. Hershey Medical Center, Hershey, Pennsylvania.
Quynh-Thu LeDepartment of Radiation Oncology, Stanford University, Stanford, California.
Jeffrey C BuchsbaumDivision of Cancer Treatment and Diagnosis, Radiation Research Program, National Cancer Institute, Bethesda, Maryland. Electronic address: jeff.buchsbaum@nih.gov.

Funding

NRG Oncology Network Group Operations Center - GY9 BIQSFP Reports/BudgetsU10CA180868 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI NORMAN WOLMARK · 2014 to 2026
$206.8M
IROC: Enhancing local enrolling site radiological data capture capabilities for NCTN trialsU24CA180803 · NCI · AMERICAN COLLEGE OF RADIOLOGY · PI Thomas J. FitzGerald, MICHAEL V KNOPP · 2014 to 2026
$116.2M
Staff InvestigatorsP30CA093373 · NCI · UNIVERSITY OF CALIFORNIA DAVIS · PI KC KENT LLOYD · 2002 to 2026
$84.9M
Translational Studies in FLASH Particle RadiotherapyP01CA257904 · NCI · UNIVERSITY OF PENNSYLVANIA · PI Mary E. Putt · 2022 to 2026
$14.2M
Project 3: Enhanced Sensitivity of Tumors to Proton Beam Therapy: Mechanisms and Biomarkers.P01CA261669 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI TITT, UWE · 2021 to 2025
$14.0M
Radiobioeffect Modeling of αRPTP01CA272222 · NCI · JOHNS HOPKINS UNIVERSITY · PI Ana Ponce Kiess · 2023 to 2026
$12.8M
Dose-Response in Radionuclide TherapyR01CA116477 · NCI · JOHNS HOPKINS UNIVERSITY · PI HOBBS, ROBERT FRANCOIS, SGOUROS, GEORGE · 2006 to 2022
$7.1M
High Energy and Spatial Resolution Multi-Isotope SPECT Imaging of Targeted Alpha-Emitters and their DaughtersU01EB031798 · NIBIB · JOHNS HOPKINS UNIVERSITY · PI DU, YONG, FREY, ERIC C. · 2021 to 2025
$3.8M
UCDCCC NCTN U10 ProgramU10CA180846 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI GANDARA, DAVID R, VALICENTI, RICHARD · 2014 to 2018
$3.3M
Combination Radiopharmaceutical Therapy and External Beam RadiotherapyR01CA240779 · NCI · JOHNS HOPKINS UNIVERSITY · PI HOBBS, ROBERT FRANCOIS, LADENSON, PAUL W · 2020 to 2025
$2.8M
Combined Biologic and Radiopharmaceutical Therapy of Breast CancerR01CA187037 · NCI · JOHNS HOPKINS UNIVERSITY · PI SGOUROS, GEORGE · 2015 to 2019
$2.4M
Reducing cardiac toxicity with deep learning and MRI-guided radiation therapyR01HL153720 · NHLBI · UNIVERSITY OF WISCONSIN-MADISON · PI GLIDE-HURST, CARRI KAYE · 2021 to 2024
$2.2M
NCI NIH HHS P01 CA257904NCI NIH HHS P01 CA261669NCI NIH HHS P01 CA272222NCI NIH HHS P30 CA093373NCI NIH HHS R01 CA116477NCI NIH HHS R01 CA187037NCI NIH HHS R01 CA240779NCI NIH HHS R44 CA254844NCI NIH HHS U10 CA180846NCI NIH HHS U10 CA180868NCI NIH HHS U24 CA180803NHLBI NIH HHS R01 HL153720NIBIB NIH HHS U01 EB031798
6 · The paper itself

Abstract

This white paper examines the potential of pioneering technologies and artificial intelligence-driven solutions in advancing clinical trials involving radiation therapy. As the field of radiation therapy evolves, the integration of cutting-edge approaches such as radiopharmaceutical dosimetry, FLASH radiation therapy, image guided radiation therapy, and artificial intelligence promises to improve treatment planning, patient care, and outcomes. Additionally, recent advancements in quantum science, linear energy transfer/relative biological effect, and the combination of radiation therapy and immunotherapy create new avenues for innovation in clinical trials. The paper aims to provide an overview of these emerging technologies and discuss their challenges and opportunities in shaping the future of radiation oncology clinical trials. By synthesizing knowledge from experts across various disciplines, this white paper aims to present a foundation for the successful integration of these innovations into radiation therapy research and practice, ultimately enhancing patient outcomes and revolutionizing cancer care.

Indexed as

Artificial IntelligenceClinical Trials as TopicNeoplasmsRadiation OncologyForecastingHumansImmunotherapyRadiotherapy, Image-Guided

Identifiers

PMID39848295
PMCPMC12086052

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.